Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Burosumab, a fully human monoclonal antibody to FGF23, is the only approved treatment for X-linked hypophosphatemia (XLH), a rare genetic disorder characterized by renal phosphate wasting and substantial cumulative musculoskeletal morbidity. During an initial 24-week randomized, controlled trial, 13...

Full description

Bibliographic Details
Main Authors:	Portale, A, Carpenter, T, Brandi, M, Briot, K, Cheong, H, Cohen-Solal, M, Crowley, R, Jan De Beur, S, Eastell, R, Imanishi, Y, Imel, E, Ing, S, Ito, N, Javaid, M, Kamenicky, P, Keen, R, Kubota, T, Lachmann, R, Perwad, F, Pitukcheewanont, P, Ralston, S, Takeuchi, Y, Tanaka, H, Weber, T, Yoo, H, Zhang, L, Theodore-Oklota, C, Mealiffe, M, San Martin, J, Insogna, K
Format:	Journal article
Published:	Springer Nature 2019

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Similar Items